Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189010

SCHEMBL7189010

SCHEMBL7189010

COc1cccc(Cl)c1P(=O)(C(=O)c1ccccc1)C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A9 P48067 1/20 0.41
▸ RORC P51449 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ MRGPRX4 Q96LA9 3/20 0.37
▸ TAS1R3 Q7RTX0 1/20 0.37
▸ TAS1R1 Q7RTX1 1/20 0.37
▸ TAS1R2 Q8TE23 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181915 0.88 MAPT (0.41) SLC6A9RORCLMNAGAAMAPT
SCHEMBL7178228 0.87 CA12 (0.44) LMNAGAAMAPTRAB9AFABP4
SCHEMBL7186756 0.87 CA12 (0.41) RORCLMNAMAPTRAB9AMEN1
SCHEMBL7180969 0.85 RORC (0.41) RORCGAAMAPTTYK2
SCHEMBL7188630 0.84 TRPM4 (0.41) MAPTRAB9APOLBKMT2ATAS1R3
SCHEMBL7188367 0.83 MAOB (0.40) SLC6A9LMNAGAAMAPTRAB9A
SCHEMBL7175566 0.83 TRPM4 (0.41) MAPTRAB9ATYK2FABP4ITGB1
SCHEMBL7188697 0.82 SLC6A9 (0.42) SLC6A9RORCLMNAGAAMAPT
SCHEMBL7175979 0.82 ABCG2 (0.42) GAAMAPTRAB9AMEN1TP53
SCHEMBL7190538 0.82 HPGD (0.39) SLC6A9LMNAGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SLC6A9 1065/4885RORC 1336/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SLC6A9 1323/4885RORC 1254/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.